Quick Answer
Ocugen, Inc. reported Cash and Equivalents of $39.46 million for fiscal year 2023.
Ocugen, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2023 | $39.46M | -26.2% |
| 2023 | $53.48M | -24.2% |
| 2023 | $70.58M | +3.4% |
| 2023 | $68.26M | -12.0% |
| 2022 | $77.56M | -23.7% |
| 2022 | $101.60M | -11.7% |
| 2022 | $115.00M | -11.4% |
| 2022 | $129.77M | +36.7% |
| 2021 | $94.96M | +295.0% |
| 2020 | $24.04M | +222.9% |
| 2019 | $7.44M | +357.2% |
| 2018 | $1.63M | -77.0% |
| 2017 | $7.08M | -77.8% |
| 2016 | $31.91M | +3.2% |
| 2015 | $30.91M | -47.2% |
| 2014 | $58.53M | +570.1% |
| 2013 | $8.73M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| June 30, 2024 | $15.70M | -77.8% | -40.5% |
| March 31, 2024 | $26.38M | -61.4% | -33.2% |
| December 31, 2023 | $39.46M | -49.1% | -26.2% |
| September 30, 2023 | $53.48M | -47.4% | -24.2% |
| June 30, 2023 | $70.58M | -38.6% | +3.4% |
| March 31, 2023 | $68.26M | -47.4% | -12.0% |
| December 31, 2022 | $77.56M | -18.3% | -23.7% |
| September 30, 2022 | $101.60M | -5.4% | -11.7% |
- Ocugen, Inc. showed a decrease of -26.2% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2013–2023 period, Ocugen, Inc.’s cash and equivalents has grown by 351.8% (from $8.73 million to $39.46 million).
- The most recent figure is from Ocugen, Inc.’s fiscal year 2023 report (Form 10-K), filed with the SEC on April 16, 2024.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: